Terms: = Lung cancer AND PHOX2B, 8929 AND Treatment
3 results:
1. Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell lung cancer: An Open-Label, Single-Arm, Phase 2 Study.
Peled N; Roisman LC; Levison E; Dudnik J; Chernomordikov E; Heching N; Dudnik E; Keren-Rosenberg S; Nechushtan H; Salhab A; Hershkovitz D; Tsuriel S; Hannes V; Rotem O; Lazarev I; Lichtenberg R; Granot IS; Krayim B; Shalata W; Levin D; Krutman Y; Allen AM; Blumenfeld P; Lavrenkov K; Kian W
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):105-114. PubMed ID: 36925073
[TBL] [Abstract] [Full Text] [Related]
2. Phase I/II study of resection and intraoperative cesium-131 radioisotope brachytherapy in patients with newly diagnosed brain metastases.
Wernicke AG; Yondorf MZ; Peng L; Trichter S; Nedialkova L; Sabbas A; Kulidzhanov F; Parashar B; Nori D; Clifford Chao KS; Christos P; Kovanlikaya I; Pannullo S; Boockvar JA; Stieg PE; Schwartz TH
J Neurosurg; 2014 Aug; 121(2):338-48. PubMed ID: 24785322
[TBL] [Abstract] [Full Text] [Related]
3. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Ichou FA; den Ouden E; Versteeg R; Caron HN; Tytgat GA; van der Schoot CE
Clin Cancer Res; 2012 Feb; 18(3):808-14. PubMed ID: 22142825
[TBL] [Abstract] [Full Text] [Related]
